Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
290 participants
INTERVENTIONAL
2025-07-22
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
L9LS MAb in Malian Adults
NCT05816330
Anti-malaria MAb in Malian Children
NCT05304611
L9LS-R21 Interaction
NCT07208760
Anti-malaria MAb in Kenyan Children
NCT05400655
Trial to Evaluate L9LS in Healthy Adults
NCT05019729
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a randomized, double-blind, placebo-controlled study mainly in WOCBP, weight-stratified (N=270 total), with 2 treatment arms: L9LS 1800 mg SC (n=180) and placebo (n=90) to assess safety and protective efficacy of L9LS. A separate open label male only arm (n=20) will assess sex-differences in the pharmacokinetics (PK) of L9LS at a dose of 1800 mg SC. Male participants will be enrolled during the same time period as the WOCBP arm.
Participants will receive the study agent and be followed at visits on study Days 1, 3, 7, 14, 21, and 28 days later, and once every 2 weeks thereafter through 24 weeks. Primary study assessments include physical examination, blood collection for identification of Pf infection and other research laboratory evaluations.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
L9LS in healthy Malian WOCBP
Single dose of 1800 mg L9LS SC
A human monoclonal antibody to protect against Plasmodium falciparum.
Placebo in healthy Malian WOCBP
Placebo
Normal saline
L9LS in healthy Malian adult males
Single dose of 1800 mg L9LS SC
A human monoclonal antibody to protect against Plasmodium falciparum.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Single dose of 1800 mg L9LS SC
A human monoclonal antibody to protect against Plasmodium falciparum.
Placebo
Normal saline
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Males aged ≥18 and ≤49 years (no weight restrictions).
3. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
4. In good general health and without clinically significant medical history.
5. Able to provide informed consent.
6. Willing to have blood samples and data stored for future research.
7. Resides in or near Kalifabougou, Faladje, or Torodo, Mali, and available for the duration of the study.
8. Females of childbearing potential must be willing to use reliable contraception from 21 days prior to study Day 0 through the final study visit as described below.
1. Reliable methods of birth control include 1 of the following: confirmed pharmacologic contraceptives via parenteral delivery or intrauterine or implantable device.
Exclusion Criteria
2. Currently breastfeeding.
3. Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the participant to understand and comply with the study protocol.
4. Study comprehension examination score of \<80% correct or per investigator discretion.
5. Hemoglobin, WBC, absolute neutrophil, or platelet count outside the local laboratory-defined limits of normal. (Participants may be included at the investigator's discretion for "not clinically significant" values.)
6. Alanine transaminase (ALT) or creatinine (Cr) level above the local laboratory-defined upper limit of normal. (Participants may be included at the investigator's discretion for "not clinically significant" values.)
7. Infected with HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV).
8. Known or documented sickle cell disease by history. (Note: Known sickle cell trait is NOT exclusionary.)
9. Clinically significant abnormal electrocardiogram (ECG; QTc \>460 or other significant abnormal findings, including unexplained tachycardia or bradycardia).
10. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies including urinalysis.
11. Receipt of any investigational product within the past 30 days.
12. Participation or planned participation in an interventional trial with an investigational product until the last required protocol visit. \[Note: Past, current, or planned participation in observational studies is NOT exclusionary; participation in the placebo arm of the Mali adult CIS43LS MAb trial (ClinicalTrials.gov Identifier: NCT04329104) or the placebo arm of the Mali adult L9LS Mab trial (ClinicalTrials.gov Identifier: NCT05816330) is NOT exclusionary.\]
13. Medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.
14. History of a severe allergic reaction or anaphylaxis.
15. Severe asthma (defined as asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past 2 years, or that has required the use of oral or parenteral corticosteroids at any time during the past 2 years).
16. Pre-existing autoimmune or antibody-mediated diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjögren's syndrome, or autoimmune thrombocytopenia.
17. Salivary gland disorder diagnosed by a doctor (e.g., parotitis, sialadenitis, sialolithiasis, salivary gland tumors).
18. Known immunodeficiency syndrome.
19. Known asplenia or functional asplenia.
20. Use of chronic (≥14 days) oral or IV corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone \>10 mg/day) or immunosuppressive drugs within 30 days of day 0.
21. Receipt of a live vaccine within the past 4 weeks or a killed vaccine within the past 2 weeks prior to study agent administration.
22. Receipt of immunoglobulins and/or blood products within the past 6 months.
23. Previous receipt of an investigational malaria vaccine or MAb in the last 5 years.
24. Known allergies or contraindication against artemether lumefantrine.
25. Other condition(s) that, in the opinion of the investigator, would jeopardize the safety or rights of a participant participating in the trial, interfere with the evaluation of the study objectives, or render the participant unable to comply with the protocol.
18 Years
49 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
Malaria Research and Training Center, Bamako, Mali
OTHER
University of the Sciences, Techniques and Technologies of Bamako
OTHER
Faculté de Médecine Pharmacie d'Odontostomatologie (FMOS)
UNKNOWN
University of Washington
OTHER
Harvard School of Public Health (HSPH)
OTHER
Indiana University School of Medicine
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Crompton, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
National Institutes of Health (NIH)
Kassoum Kayentao, MD, MPH, PhD
Role: PRINCIPAL_INVESTIGATOR
Faculté de Médecine Pharmacie d'Odontostomatologie (FMOS)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faladje MRTC Clinic
Faladié, Koulikoro, Mali
Kalifabougou MRTC Clinic
Kalifabougou, Koulikoro, Mali
Torodo MRTC Clinic
Torodo, Koulikoro, Mali
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
L9LS in WOCBP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.